BP000136-CYT-391: Recombinant Rat IL-13
Source: E. coli-derived.
Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 10-100 ug/ml corresponding to a Specific Activity of 10,000-100,000 IU/mg.
Purity > 95%, by SDS-PAGE.BP000136-CYT-446: Recombinant Human IL-13
Source: E. coli-derived.
The ED50 was determined by the dose dependent prolifiration of TF-1 cells and was found to be < 1 ug/ml, corresponding to a specific activity of 1 MIU/mg.
Purity > 95%, by SDS-PAGE and RP-HPLC.BP000136-CYT-489: Recombinant Human IL-13, His Tag
Source: E. coli-derived.
Purity > 95%, by SDS--PAGE and RP-HPLC.BP000136-CYT-682: Recombinant Human IL-13 Variant
Source: E. coli-derived.
The ED50 was determined by the dose dependent prolifiration of TF-1 cells and was found to be < 1 ug/ml, corresponding to a specific activity of >1,000,000 units/mg. This analog has also been shown to exhibit increased in vivo activity compared to wild type IL-13.
Purity > 95%, by SDS--PAGE and RP-HPLC.BP000139-CYT-623: Recombinant Human IL-17 A/F Heterodimer
Source: E. coli-derived.
Purity > 98%, by SDS-PAGE.BP000139-CYT-640: Recombinant Mouse IL-17 A/F Heterodimer
Source: E. coli-derived.
Purity > 97%, by SDS-PAGE.BP000139-CYT-677: Recombinant Rat IL-17 A/F Heterodimer
Source: E. coli-derived.
Purity > 97%, by SDS-PAGE.BP000141-CYT-576: Recombinant Rat Interleukin-17 Epsilon (IL-17E) Protein
Source: E. coli-derived.
Purity: > 95% by SDS-PAGE and RP-HPLC.BP000141-CYT-583: Recombinant Human Interleukin-17 Epsilon (IL-17E) Protein
Source: E. coli-derived.
Purity: > 95% by SDS-PAGE and RP-HPLC.BP000151-CYT-104: Recombinant Human IL-28A, HEK
Source: HEK-derived.
The specific activity was determined by the dose dependent protection of the cytopathic effect on A549 cells (human lung adenocarcinoma epithelial cell line) that were challenged with encephalomyocarditis (EMC) virus and is typically 0.5-5 ug/ml.
Purity: > 95% as obsereved by SDS-PAGE.